Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BI 1821736 |
| Synonyms | |
| Therapy Description |
BI 1821736 is an oncolytic vesicular stomatitis virus engineered to express the non-neurotopic GP glycoprotein and a CD80 Fc fragment, which may induce a cytotoxic response in tumor cells and an antitumor immune response (J Clin Oncol 42, 2024 (suppl 16; abstr TPS2688), NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BI 1821736 | BI-1821736|BI1821736 | BI 1821736 is an oncolytic vesicular stomatitis virus engineered to express the non-neurotopic GP glycoprotein and a CD80 Fc fragment, which may induce a cytotoxic response in tumor cells and an antitumor immune response (J Clin Oncol 42, 2024 (suppl 16; abstr TPS2688), NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05839600 | Phase I | BI 1821736 | A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer | Terminated | USA | SWE | ESP | CAN | 0 |